Parameter
| Biomarker | sPD-L1 | Full name | Serum soluble PD-L1 | Molecular Type | protein |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Immune Regulation and Bone Metabolism | ||
| Disease | Osteoporosis (OP) | Disease Subtypes | / | ||
| Organ | Bone, Immune system | Test Sample / Technology Platform | Serum (ELISA, flow cytometry) | ||
| Pathobiological Mechanisms | Glucocorticoids induce immunosuppression, and elevated sPD-L1 suppresses T cell activity, indirectly promoting osteoclast activation | ||||
| Clinical Availability Status | Research phase | ||||
| Notes and Dynamics | It is positively correlated with the dosage of glucocorticoids; patients with sPD-L1>2 ng/mL exhibit a 25% reduced response rate to bisphosphonate therapy. | ||||